Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Braz J Biol ; 84: e283646, 2024.
Article in English | MEDLINE | ID: mdl-39109727

ABSTRACT

Candida albicans is the main fungal species involved in oral candidiasis, and its increasing resistance to pharmacological treatment encourages the search for improved antifungal agents. Lavandula dentata L. essential oil (LD-EO) has been recognized for its antimicrobial activity, but little is known about its role against oral C. albicans. This study evaluated the antifungal and antibiofilm activities, mechanisms of action, and toxicity of LD-EO from Brazil against oral strains of C. albicans. Antifungal activity was assessed based on Minimum Inhibitory Concentration (MIC), Minimum Fungicidal Concentration (MFC), association study with miconazole (Checkerboard method), and sorbitol and ergosterol assays. Inhibition of biofilm formation and disruption of preformed biofilm were considered when studying the effects of the product. Additionally, the toxicity of LD-EO was evaluated by a hemolysis assay on human erythrocytes. Phytochemical analysis by gas chromatography-mass spectrometry identified eucalyptol (33.1%), camphor (18.3%), and fenchone (15.6%) as major constituents. The test substance showed mainly fungicidal activity (MIC100 = 8 µg/mL; MFC = 16 µg/mL), including against two miconazole-resistant isolates of C. albicans. The effects of LD-EO were synergistic with those of miconazole and appeared not to involve damage to the fungal cell wall or plasma membrane. Its effectiveness in inhibiting biofilm formation was higher than the effect of disrupting preformed biofilm. Finally, the product exhibited low hemolytic activity at MIC. Based on the favorable and novel results described here, LD-EO could constitute a promising therapeutic alternative for oral candidiasis, including miconazole-resistant cases.


Subject(s)
Antifungal Agents , Biofilms , Candida albicans , Lavandula , Microbial Sensitivity Tests , Oils, Volatile , Biofilms/drug effects , Oils, Volatile/pharmacology , Oils, Volatile/chemistry , Antifungal Agents/pharmacology , Candida albicans/drug effects , Candida albicans/physiology , Humans , Lavandula/chemistry , Gas Chromatography-Mass Spectrometry , Hemolysis/drug effects
2.
Lett Appl Microbiol ; 72(3): 299-306, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33037668

ABSTRACT

Carvacrol has been recognized as an efficient growth inhibitor of food pathogens. However, carvacrol oil is poorly water-soluble and can be oxidized, decomposed or evaporated when exposed to the air, light, or heat. To overcome these limitations, a carvacrol nanoemulsion was developed and its antimicrobial activity against food pathogens evaluated in this study. The nanoemulsion containing 3% carvacrol oil, 9% surfactants (HLB 11) and 88% water, presented good stability over a period of 90 days. In general, the carvacrol nanoemulsion (MIC: 256 µg ml-1 for E. coli and Salmonella spp., 128 µg ml-1 for Staphylococcus aureus and Pseudomonas aeruginosa) exhibited improved antimicrobial activity compared to the free oil. The carvacrol nanoemulsion additionally displayed bactericidal activity against Escherichia coli, P. aeruginosa and Salmonella spp. Therefore, the results of this study indicated that carvacrol oil nanoemulsions can potentially be incorporated into food formulations, wherein their efficacy for the prevention and control of microbial growth could be evaluated.


Subject(s)
Anti-Bacterial Agents/pharmacology , Cymenes/pharmacology , Escherichia coli/drug effects , Pseudomonas aeruginosa/drug effects , Salmonella/drug effects , Staphylococcus aureus/drug effects , Escherichia coli Infections/prevention & control , Food Microbiology , Foodborne Diseases/prevention & control , Microbial Sensitivity Tests , Monoterpenes/pharmacology , Oils, Volatile/pharmacology , Salmonella Food Poisoning/prevention & control , Staphylococcal Infections/prevention & control , Surface-Active Agents/pharmacology
3.
Immunopharmacol Immunotoxicol ; 41(1): 102-108, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30623710

ABSTRACT

Context: Pyocyanin is a typical Pseudomonas aeruginosa virulence factor, a common Gram-negative rod responsible for a wide range of severe nosocomial infections. There is evidence indicating that pyocyanin has multiple biological activities, but little is known about anti-inflammatory properties. Objective: This study investigated pyocyanin effect on nitric oxide and cytokine production in lipopolysaccharide (LPS)-activated murine peritoneal macrophages. Materials and methods: Macrophages were incubated in the presence and absence of pyocyanin (1, 5, 10, 50, and 100 µM) with and without LPS (1 µg/mL). Nitric oxide production was determined by Griess reagent and tumor necrosis factor (TNF)-α and interleukin (IL)-1ß production was assessed by enzyme-linked immunosorbent assay. In addition, pyocyanin effects on zymosan A-induced peritonitis in mice were evaluated. Results: Pyocyanin (5 and 10 µM) decreased nitric oxide, TNF-α, and IL-1ß production independent of macrophage death. On the other hand, in vivo, pyocyanin (5 mg/kg) was not able to affect leukocyte migration into the site of inflammation. Discussion and conclusion: Thus, our findings suggest that pyocyanin exerts anti-inflammatory effects on murine peritoneal macrophages, downregulating nitric oxide, TNF-α, and IL-1ß levels, which seems to be independent of cell migration. These effects may represent a mechanism of immune evasion; nevertheless more detailed studies should be performed to confirm this hypothesis.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Inflammation Mediators/metabolism , Lipopolysaccharides/toxicity , Macrophages, Peritoneal/drug effects , Macrophages, Peritoneal/immunology , Pyocyanine/pharmacology , Animals , Cell Survival/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Female , Interleukin-1beta/metabolism , Mice , Mice, Inbred C57BL , Nitric Oxide/biosynthesis , Peritonitis/immunology , Peritonitis/prevention & control , Tumor Necrosis Factor-alpha/metabolism , Zymosan
SELECTION OF CITATIONS
SEARCH DETAIL